Eva Sjökvist Saers has a PhD in pharmaceutical science from Uppsala University. Among other things, she has held the position as Pharmaceutical Director for R&D at Astra Pain Control and has had different manager positions within AstraZeneca as well as CEO of APL for more than ten years. Eva is currently working as a professional board member for various companies within life science and is the chairman of the strategic innovation program Swelife. She was previously chairman of Apotekarsocieteten and vice chairman of the trade organization SwedenBIO.
Lena Söderström has a Bachelor of Medical Science and an Executive MBA from Uppsala University. Lena Söderström has held senior positions for more than 30 years, of which 15 have been as CEO of international pharmaceutical and medical technology companies, providing her experience in project management, business development, international marketing and manufacturing. She is also a board member of the Stockholm Chamber of Commerce, Uppsala University Holding AB, Agricam AB, Biomedical Bonding and Chairman of the Board of SLU Holding AB and Inficure Bio AB.
Holding: 27,750 warrants in the company (of which 7,750 are options from option programs 2018/2023 and 2019/2024 where any recalculation has not been made in accordance with the respective option terms.)
Mikael von Euler is a Medical Doctor with a PhD from Karolinska Institutet. Mikael von Euler is a trained oncologist with more than 25 years of experience from the pharmaceutical industry. He previously held the position as Medical Director of Targovax (formerly Oncos Therapeutics), and Senior Vice President of Aprea Therapeutics. He has held several c-level positions in major pharmaceutical companies, for example as Cluster Head at Roche/Genentech, Vice President for GlaxoSmithKline and Global Product Director at AstraZeneca.
Holding: 27,750 warrants in the Company (of which 7,750 are options from option programs 2018/2023 and 2019/2024 where any recalculation has not been made in accordance with the respective option terms.)
Ebba Florin Robertsson has a Master of Science in Chemistry and a PhD in physical chemistry from the Royal Institute of Technology in Stockholm. She has more than 30 years of experience in the pharmaceutical development industry and has held positions as line- and project manager. She has also published several scientific papers and has contributed to approximately 25 patents and patent applications.
Holding: 30,000 warrants in the company (of which 10,000 are options from the option program 2019/2024 where any recalculation has not been made in accordance with the respective option terms).
Claes Post has a Master of Science in Pharmacy from Uppsala University and a PhD in Pharmaceutical Science from Linköping University. He is an Associate Professor of neuropharmacology and anaesthesiology at Uppsala University and has been an Adjunct Professor of neuropharmacology at several Swedish universities, most recently at Linköping University. Claes Post was Vice President within Preclinic at Astra Pain Control and Astra Draco between 1981 and 1994. Between 1994 and 1997 he was Senior Vice President Preclinical and Clinical CNS Drug R&D, and Vice President Preclinical and Clinical R&D within CNS at Pharmacia in Milan, Italy. He has also held the position of CEO of several start-up companies in the pharmaceutical industry, been involved in university-based technology transfers and been Investment Manager at Almi Invest AB. He is a board member of five life science companies and has published more than 140 articles in quality-reviewed scientific journals, as well as being a mentor and supervisor for medical and doctoral students.
Holding: 15,142 shares, 20,000 warrants
Per-Göran Gillberg has a PhD in medical science and is an adjunct professor of neuroscience at Uppsala University. Per-Göran's 35 years of experience in pharmacology and neuropharmacology include management positions at Kabi, Pharmacia and AstraZeneca. Today, Per-Göran holds the role of VP Development at Albireo Pharma Inc and belongs to the section for translational Alzheimer's neurobiology at Karolinska Institutet and is a board member of Alzinova AB.